Covered recipient · General Payments record
SUNIL S DHAWAN
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$3,237.07
159 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,923.65 | 154 |
| Education | $283.42 | 4 |
| Grant | $30.00 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $693.64 | 32 |
| Dermavant Sciences, Inc. | $446.50 | 27 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $321.00 | 7 |
| Janssen Biotech, Inc. | $290.50 | 10 |
| LEO Pharma Inc. | $239.25 | 22 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $212.23 | 10 |
| Amgen Inc. | $208.80 | 11 |
| PFIZER INC. | $155.58 | 10 |
| Arcutis Biotherapeutics, Inc. | $117.24 | 5 |
| GENZYME CORPORATION | $105.59 | 3 |
| Regeneron Healthcare Solutions, Inc. | $67.33 | 3 |
| E.R. Squibb & Sons, L.L.C. | $65.32 | 3 |
| Galderma Laboratories, L.P. | $60.22 | 3 |
| Organogenesis Inc. | $55.91 | 2 |
| UCB, Inc. | $52.57 | 3 |
| Janssen Research & Development, LLC | $52.40 | 1 |
| Lilly USA, LLC | $23.81 | 1 |
| STRATA Skin Sciences, Inc. | $22.46 | 1 |
| Janssen Scientific Affairs, LLC | $21.08 | 1 |
| Incyte Corporation | $13.13 | 1 |
| Biofrontera Inc. | $12.51 | 3 |
Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SUNIL S DHAWAN
NPI 1326018987 · CMS profile ID 331770
Allopathic & Osteopathic Physicians / Dermatology
FREMONT, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1326018987?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SUNIL S DHAWAN, NPI 1326018987, CMS profile ID 331770. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1326018987?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). SUNIL S DHAWAN, NPI 1326018987, CMS profile ID 331770. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1326018987?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- SUNIL S DHAWAN, NPI 1326018987, CMS profile ID 331770, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1326018987?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
159 matching records · $3,237.07 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 159.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Dermavant Sciences, Inc. | $6.23 | 09/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127861754 | CMS |
| Galderma Laboratories, L.P. | $16.98 | 09/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145294491 | CMS |
| ABBVIE INC. | $25.69 | 09/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103635546 | CMS |
| Janssen Biotech, Inc. | $14.11 | 09/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078296349 | CMS |
| Arcutis Biotherapeutics, Inc. | $21.26 | 09/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121075161 | CMS |
| ABBVIE INC. | $13.66 | 09/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103635544 | CMS |
| ABBVIE INC. | $20.30 | 09/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103635542 | CMS |
| Amgen Inc. | $25.55 | 08/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117540944 | CMS |
| Galderma Laboratories, L.P. | $21.65 | 08/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145294489 | CMS |
| PFIZER INC. | $16.40 | 08/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131880447 | CMS |
| LEO Pharma Inc. | $12.43 | 08/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152626197 | CMS |
| Regeneron Healthcare Solutions, Inc. | $25.43 | 08/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114037119 | CMS |
| Dermavant Sciences, Inc. | $14.06 | 08/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127861752 | CMS |
| Arcutis Biotherapeutics, Inc. | $19.20 | 08/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121075159 | CMS |
| Dermavant Sciences, Inc. | $99.06 | 08/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127861750 | CMS |
| LEO Pharma Inc. | $14.98 | 08/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152626195 | CMS |
| ABBVIE INC. | $25.37 | 08/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103635540 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $22.45 | 08/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1153817639 | CMS |
| ABBVIE INC. | $11.00 | 08/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103635538 | CMS |
| ABBVIE INC. | $30.06 | 07/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103635536 | CMS |
| Dermavant Sciences, Inc. | $12.38 | 07/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127861748 | CMS |
| GENZYME CORPORATION | $17.29 | 07/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139625756 | CMS |
| Janssen Scientific Affairs, LLC | $21.08 | 07/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078844757 | CMS |
| Dermavant Sciences, Inc. | $1.91 | 07/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127861746 | CMS |
| LEO Pharma Inc. | $10.43 | 07/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152626193 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $94.99 | 07/19/2024 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152205763 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $27.19 | 07/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152205773 | CMS |
| PFIZER INC. | $20.93 | 07/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131788553 | CMS |
| Dermavant Sciences, Inc. | $22.33 | 07/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127861744 | CMS |
| LEO Pharma Inc. | $13.89 | 07/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152626191 | CMS |
| Janssen Biotech, Inc. | $11.82 | 07/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078296351 | CMS |
| Amgen Inc. | $24.78 | 07/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117540942 | CMS |
| LEO Pharma Inc. | $7.67 | 07/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152626189 | CMS |
| Janssen Biotech, Inc. | $99.99 | 07/03/2024 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078296649 | CMS |
| Incyte Corporation | $13.13 | 07/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141319479 | CMS |
| ABBVIE INC. | $29.97 | 06/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103635534 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $23.55 | 06/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1153817637 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $1.52 | 06/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152205767 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $26.36 | 06/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152205769 | CMS |
| ABBVIE INC. | $33.75 | 06/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103635532 | CMS |
| PFIZER INC. | $18.85 | 06/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131609904 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $22.35 | 06/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1153817631 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $21.51 | 06/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1153817633 | CMS |
| Galderma Laboratories, L.P. | $21.59 | 06/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145294487 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $6.30 | 06/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152205765 | CMS |
| LEO Pharma Inc. | $7.05 | 06/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152626187 | CMS |
| Dermavant Sciences, Inc. | $16.13 | 05/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127861742 | CMS |
| PFIZER INC. | $4.58 | 05/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1130914542 | CMS |
| ABBVIE INC. | $12.08 | 05/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103635530 | CMS |
| Arcutis Biotherapeutics, Inc. | $40.24 | 05/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121075157 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $919,287.41 | 167 |
| PY2024 | Principal investigator | $756,940.35 | 201 |
| PY2023 | Recipient | $789.81 | 1 |
| PY2023 | Principal investigator | $547,649.68 | 157 |
| PY2022 | Principal investigator | $319,459.27 | 65 |
| PY2021 | Recipient | $89.85 | 1 |
| PY2021 | Principal investigator | $749,576.98 | 140 |
| PY2020 | Recipient | $2,374.15 | 3 |
| PY2020 | Principal investigator | $935,586.92 | 119 |
| PY2019 | Recipient | $35,982.45 | 7 |
| PY2019 | Principal investigator | $758,098.81 | 115 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
167 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $12,000.00 | 12/26/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research | A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) | No dispute reported | 06/30/2026 | 1235998222 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,380.00 | 12/25/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RES | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175344989 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,717.00 | 12/22/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226090784 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,956.10 | 12/22/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226116645 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,900.00 | 12/18/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246431008 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,480.00 | 12/15/2025 | Non-covered Recipient Entity Center for Dermatology Clinical Research, Inc. | Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis | No dispute reported | 06/30/2026 | 1244051685 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $607.50 | 12/08/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226116635 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,054.00 | 12/08/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226116641 |
| Principal investigator 1 | Incyte Corporation | $8,435.90 | 12/04/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514874 |
| Principal investigator 1 | Incyte Corporation | $10,027.20 | 12/04/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514878 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $7,100.00 | 12/03/2025 | Non-covered Recipient Entity CTR FOR DERMATOLOGY CLINICAL RESEARCH | AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS | No dispute reported | 06/30/2026 | 1232947079 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,380.00 | 12/01/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RES | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175344981 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,909.20 | 12/01/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICA | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289053 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,781.60 | 11/26/2025 | Non-covered Recipient Entity Center for Dermatology Clinical Research, Inc. | A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo | No dispute reported | 06/30/2026 | 1244051701 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $13,129.60 | 11/26/2025 | Non-covered Recipient Entity Center for Dermatology Clinical Research, Inc. | A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo | No dispute reported | 06/30/2026 | 1244051703 |
| Principal investigator 1 | Incyte Corporation | $5,840.00 | 11/25/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514851 |
| Principal investigator 1 | Incyte Corporation | $2,211.30 | 11/25/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514860 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $11,315.00 | 11/24/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH | Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1252797002 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,950.00 | 11/18/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226108615 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,716.20 | 11/17/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226090779 |
| Principal investigator 1 | Incyte Corporation | $1,368.00 | 11/14/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514864 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $65.00 | 11/13/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226108610 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,118.75 | 11/13/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246431006 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,812.50 | 11/10/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226116628 |
| Principal investigator 1 | Incyte Corporation | $1,003.50 | 11/07/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514855 |
| Principal investigator 1 | Incyte Corporation | $4,930.60 | 11/06/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo | No dispute reported | 06/30/2026 | 1240514868 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $77.00 | 11/03/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INCORPORATION | A Multicenter, Randomized, Participant- and Investigator -Blinded, Placebo-controlled, Phase 2a Study to Assess the Efficacy, Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1190305181 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $8,197.50 | 10/30/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246431002 |
| Principal investigator 1 | Incyte Corporation | $1,937.70 | 10/29/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514847 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $13,385.00 | 10/28/2025 | Non-covered Recipient Entity CTR FOR DERMATOLOGY CLINICAL RESEARCH | AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS | No dispute reported | 06/30/2026 | 1232946765 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,200.00 | 10/27/2025 | Non-covered Recipient Entity Center for Dermatology Clinical Research, Inc. | A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo | No dispute reported | 06/30/2026 | 1244051699 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $12,000.00 | 10/23/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | A Multicenter, Randomized, Participant- and Investigator -Blinded, Placebo-controlled, Phase 2a Study to Assess the Efficacy, Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1190309472 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $7,068.75 | 10/23/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246431004 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,500.00 | 10/22/2025 | Non-covered Recipient Entity Ctr For Derm Clinic Rsrch | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175170180 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,969.50 | 10/22/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICA | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287283 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $11,089.00 | 10/20/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226116623 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $895.00 | 10/16/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226108621 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,174.14 | 10/14/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INCORPORATION | A Multicenter, Randomized, Participant- and Investigator -Blinded, Placebo-controlled, Phase 2a Study to Assess the Efficacy, Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1190305179 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,500.00 | 10/14/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226116618 |
| Principal investigator 1 | Incyte Corporation | $1,699.20 | 10/09/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514843 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $8,165.64 | 10/09/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246431000 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $243.78 | 10/08/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INCORPORATION | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190305183 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,847.94 | 10/08/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INCORPORATION | A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup | No dispute reported | 06/30/2026 | 1190305187 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $15,300.00 | 10/06/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226116607 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,321.90 | 10/06/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226116612 |
| Principal investigator 1 | Incyte Corporation | $3,010.50 | 10/03/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514839 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $13,845.00 | 10/03/2025 | Non-covered Recipient Entity CTR FOR DERMATOLOGY CLINICAL RESEARCH | AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS | No dispute reported | 06/30/2026 | 1232946444 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $14,446.90 | 10/01/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICA | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286069 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $10,400.00 | 09/30/2025 | Non-covered Recipient Entity Center for Dermatology Clinical Research, Inc. | Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis | No dispute reported | 06/30/2026 | 1244051683 |
| Principal investigator 1 | Janssen Research & Development, LLC | $172.00 | 09/29/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RES EARCH INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175344972 |
| Principal investigator 1 | Incyte Corporation | $2,790.90 | 09/23/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514836 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $11,926.40 | 09/17/2025 | Non-covered Recipient Entity Center for Dermatology Clinical Research, Inc. | A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo | No dispute reported | 06/30/2026 | 1244051697 |
| Principal investigator 1 | Incyte Corporation | $1,094.40 | 09/12/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514827 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $160.00 | 09/08/2025 | Non-covered Recipient Entity Center for Dermatology Clinical Research, Inc. | Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis | No dispute reported | 06/30/2026 | 1244051681 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,507.20 | 09/08/2025 | Non-covered Recipient Entity Center for Dermatology Clinical Research, Inc. | A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo | No dispute reported | 06/30/2026 | 1244051695 |
| Principal investigator 1 | Incyte Corporation | $3,806.10 | 09/04/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514831 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,506.00 | 09/04/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RES EARCH INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175344965 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $14,345.00 | 09/04/2025 | Non-covered Recipient Entity CTR FOR DERMATOLOGY CLINICAL RESEARCH | AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS | No dispute reported | 06/30/2026 | 1232946236 |
| Principal investigator 1 | Incyte Corporation | $1,699.20 | 08/26/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514816 |
| Principal investigator 1 | Incyte Corporation | $1,091.70 | 08/21/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514820 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,200.00 | 08/20/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223284445 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $325.00 | 08/19/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226098099 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,602.00 | 08/11/2025 | Non-covered Recipient Entity Ctr For Derm Clinic Rsrch | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175170316 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,034.90 | 08/11/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226116597 |
| Principal investigator 1 | Incyte Corporation | $6,789.60 | 08/07/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514823 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $21,476.77 | 08/07/2025 | Non-covered Recipient Entity Center for Dermatology Clinical Research, Inc. | A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo | No dispute reported | 06/30/2026 | 1244051693 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $9,525.00 | 08/06/2025 | Non-covered Recipient Entity CTR FOR DERMATOLOGY CLINICAL RESEARCH | AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS | No dispute reported | 06/30/2026 | 1232946055 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $7,000.00 | 08/06/2025 | Non-covered Recipient Entity CTR FOR DERMATOLOGY CLINICAL RESEARCH | AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS | No dispute reported | 06/30/2026 | 1232946059 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $5,975.00 | 08/06/2025 | Non-covered Recipient Entity CTR FOR DERMATOLOGY CLINICAL RESEARCH | AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS | No dispute reported | 06/30/2026 | 1232946063 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $9,000.00 | 08/04/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246430998 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,999.10 | 08/01/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283715 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,919.10 | 08/01/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283717 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,566.00 | 07/14/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226116577 |
| Principal investigator 1 | Incyte Corporation | $7,104.60 | 07/10/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514811 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,608.75 | 07/10/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226098110 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,698.00 | 07/07/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226116583 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,830.60 | 07/01/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223281982 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,760.00 | 06/26/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RES EARCH INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175344996 |
| Principal investigator 1 | Incyte Corporation | $820.80 | 06/24/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514798 |
| Principal investigator 1 | Incyte Corporation | $2,802.60 | 06/19/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514803 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,236.00 | 06/16/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226116558 |
| Principal investigator 1 | Incyte Corporation | $3,567.60 | 06/12/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514807 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $88.00 | 06/11/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184205829 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $88.00 | 06/11/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184205831 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $88.00 | 06/11/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184205833 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $88.00 | 06/11/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184205835 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,534.50 | 06/09/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226116554 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,890.50 | 06/04/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223280748 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $12,528.00 | 06/01/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INCORPORATION | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190305185 |
| Principal investigator 1 | Incyte Corporation | $1,003.50 | 05/28/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514795 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,100.00 | 05/27/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226116540 |
| Principal investigator 1 | Incyte Corporation | $78.30 | 05/22/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514791 |
| Principal investigator 1 | Eli Lilly and Company | $11,102.00 | 05/21/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187875575 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,582.00 | 05/19/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226116566 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,400.00 | 05/19/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226116571 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,040.00 | 05/15/2025 | Non-covered Recipient Entity Ctr For Derm Clinic Rsrch | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175170188 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,898.90 | 05/12/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226116534 |
| Principal investigator 1 | Incyte Corporation | $4,542.30 | 05/08/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514786 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $262.90 | 05/08/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184194091 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,861.85 | 05/02/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223278902 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,000.00 | 05/01/2025 | Non-covered Recipient Entity Center for Dermatology Clinical Research, Inc. | A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo | No dispute reported | 06/30/2026 | 1244051691 |
| Principal investigator 1 | Incyte Corporation | $899.10 | 04/28/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514766 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,160.00 | 04/28/2025 | Non-covered Recipient Entity Ctr For Derm Clinic Rsrch | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175170366 |
| Principal investigator 1 | Eli Lilly and Company | $74,418.11 | 04/23/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE RANGING STUDY OF LY4100511 (DC-853) FOR THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE-TO SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 1187880897 |
| Principal investigator 1 | Incyte Corporation | $4,254.30 | 04/15/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514771 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,345.00 | 04/14/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226116513 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,841.60 | 04/11/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278008 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $818.75 | 04/10/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226097922 |
| Principal investigator 1 | Incyte Corporation | $855.90 | 04/08/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514775 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $87.00 | 04/07/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184181818 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $87.00 | 04/07/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184181820 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $87.00 | 04/07/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184181822 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $87.00 | 04/07/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184181824 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $87.00 | 04/07/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184181826 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $87.00 | 04/07/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184181828 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $87.00 | 04/07/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184181830 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $87.00 | 04/07/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184181832 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $87.00 | 04/07/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184181834 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $87.00 | 04/07/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184181836 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 04/07/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184181838 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $907.50 | 04/07/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184181840 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $742.50 | 04/07/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184181842 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $907.50 | 04/07/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184181844 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $907.50 | 04/07/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184181846 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $907.50 | 04/07/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184181848 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 04/07/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184181850 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 04/07/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184181852 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,534.50 | 04/07/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226116490 |
| Principal investigator 1 | Incyte Corporation | $3,610.80 | 04/01/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514779 |
| Principal investigator 1 | Incyte Corporation | $934.20 | 04/01/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514783 |
| Principal investigator 1 | Eli Lilly and Company | $14,549.00 | 03/27/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187876999 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,192.00 | 03/27/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RES EARCH INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175345003 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,231.85 | 03/26/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223277039 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $19,298.00 | 03/24/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226116478 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,300.00 | 03/24/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226116482 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $12,250.00 | 03/20/2025 | Non-covered Recipient Entity Center for Dermatology Clinical Research, Inc. | Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis | No dispute reported | 06/30/2026 | 1244051679 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,000.00 | 03/20/2025 | Non-covered Recipient Entity Center for Dermatology Clinical Research, Inc. | A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo | No dispute reported | 06/30/2026 | 1244051687 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,000.00 | 03/20/2025 | Non-covered Recipient Entity Center for Dermatology Clinical Research, Inc. | A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo | No dispute reported | 06/30/2026 | 1244051689 |
| Principal investigator 1 | Incyte Corporation | $3,716.10 | 03/11/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514762 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,173.50 | 03/10/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226116442 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,800.00 | 03/04/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults | No dispute reported | 06/30/2026 | 1226116448 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,120.00 | 03/03/2025 | Non-covered Recipient Entity Ctr For Derm Clinic Rsrch | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175170254 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,824.20 | 02/27/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226116473 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,528.40 | 02/26/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223275613 |
| Principal investigator 1 | Incyte Corporation | $13,230.90 | 02/25/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514889 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,076.90 | 02/21/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223275447 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,300.00 | 02/18/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226116464 |
| Principal investigator 1 | Incyte Corporation | $52.48 | 02/05/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY COSMETIC AND LASER SURGERY | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240514896 |
| Principal investigator 1 | Incyte Corporation | $4.25 | 02/05/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY COSMETIC AND LASER SURGERY | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240514900 |
| Principal investigator 1 | Incyte Corporation | $93.30 | 02/05/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY COSMETIC AND LASER SURGERY | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240514909 |
| Principal investigator 1 | Incyte Corporation | $77.75 | 02/05/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY COSMETIC AND LASER SURGERY | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240514913 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,730.80 | 02/03/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223274631 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $87,328.67 | 02/01/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INCORPORATION | A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup | No dispute reported | 06/30/2026 | 1190305189 |
| Principal investigator 1 | Eli Lilly and Company | $11,991.00 | 01/29/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | AN OPEN-LABEL, 24-WEEK STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AND SKIN OF COLOR | No dispute reported | 06/30/2026 | 1187878901 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,964.50 | 01/27/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1226116457 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,543.00 | 01/24/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RES EARCH INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175345010 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,800.00 | 01/21/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy and Safety of Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226116469 |
| Principal investigator 1 | Incyte Corporation | $273.60 | 01/17/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514885 |
| Principal investigator 1 | Incyte Corporation | $230.00 | 01/16/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo | No dispute reported | 06/30/2026 | 1240514892 |
| Principal investigator 1 | Janssen Research & Development, LLC | $382.00 | 01/16/2025 | Non-covered Recipient Entity Ctr For Derm Clinic Rsrch | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175170383 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,345.00 | 01/16/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226116520 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $65.00 | 01/16/2025 | Non-covered Recipient Entity Center For Dermatology Clinical Research Inc | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | No dispute reported | 06/30/2026 | 1226116528 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,005.15 | 01/08/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH INC | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223273777 |
| Principal investigator 1 | Incyte Corporation | $9,396.90 | 01/07/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240514882 |
| Principal investigator 1 | Amgen Inc. | $3,275.05 | 01/02/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY CLINICAL RESEARCH, INC. | P2 Moderate-Severe pDLE | No dispute reported | 06/30/2026 | 1246640163 |
| Principal investigator 1 | Incyte Corporation | $45.80 | 01/02/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY COSMETIC AND LASER SURGERY | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240514905 |
| Principal investigator 1 | Incyte Corporation | $97.08 | 01/02/2025 | Non-covered Recipient Entity CENTER FOR DERMATOLOGY COSMETIC AND LASER SURGERY | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240514918 |